UNSPSC 51294703: Pirisudanol or pyrisuccideanol

This classification denotes a cns stimulant with the molecular formula C16H24N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W618Z2SMVL. European Medicines Agency schedules pirisudanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09919MIG. The term PIRISUDANOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21. ).

PIRISUDANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pirisudanol or pyrisuccideanol bears US NLM identifiers UMLS ID C0072732 and NCI Concept Code C66427. SMILES: O(Cc1c(c(O)c(nc1)C)CO)C(=O)CCC(=O)OCCN(C)C.

UNSPSC 51294703 Pirisudanol or pyrisuccideanol is a Commodity code with minimal direct relevance to recent state and local procurement activity. The code nominally covers a specific pharmaceutical ingredient, but the recent opportunities tagged to this code do not procure pirisudanol itself. Instead, they solicit naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products — a mismatch between the code's narrow chemical scope and the actual purchasing patterns state and local bodies are executing. The code shows no current market activity for the named substance among state and local issuers. Naloxone procurement, therapeutic pharmacy initiatives, and generic pharmaceutical supply contracts operate under different UNSPSC classifications and represent the substantive opportunity set in this tagged cluster.

The three recent opportunities illustrate the broader pharmaceutical and health-supply procurement activity among state and local bodies but do not reflect pirisudanol purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026, closing July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026, closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026. Firms tracking pharmaceutical supply, health emergency response, or state cooperative purchasing may benefit from monitoring these categories, but pirisudanol itself does not appear in active state and local procurement pipelines as of mid-2026.